argenx NV ADR (ARGX)vsKyverna Therapeutics, Inc. Common Stock (KYTX)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
KYTX
Kyverna Therapeutics, Inc. Common Stock
$7.64
-3.17%
HEALTHCARE · Cap: $470.30M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
KYTX
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for KYTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : KYTX
The strongest argument for KYTX centers on Debt/Equity, Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : KYTX
The primary concerns for KYTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while KYTX is a value play — different risk/reward profiles.
KYTX carries more volatility with a beta of 3.35 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 26/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Kyverna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kyverna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced immunotherapies for autoimmune diseases and serious medical conditions. Utilizing its cutting-edge genetically engineered T-cell technology, the firm aims to enhance the immune system's capabilities, offering targeted solutions for effective disease management. With a strategic focus on cellular therapies, Kyverna is well-positioned within the biopharmaceutical sector, presenting compelling opportunities for institutional investors looking to support transformative treatments and capitalize on growth in the immunotherapy landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?